爱上海,上海419论坛,上海龙凤419 - Powered by 上海夜网AH

Potdevin takes over from Jake Burton Carpenter as CEO

first_imgBURTON PRESIDENT LAURENT POTDEVIN PROMOTED TO CEO9/29/05Burlington, VT – Burton’s President Laurent Potdevin will assume thetitle of President and CEO, formalizing his role overseeing all Burtonbrands and shared services on a global level including Burton Snowboards,Gravis, R.E.D., ANON, Analog and The Program. Since Jake Burton Carpenterfounded the company in 1977, he has been the sole CEO. “I couldn’t be more stoked about this promotion for Laurent,” says Jake.”Laurent has worked hard and been tough, but fair in his leadership. Hehas made us all better at what we do. I have been here close to 30 years,and in that time I have never felt that someone was deserving of the CEOtitle until now.” Laurent earned this unprecedented promotion by making an impressiveimpact on the company as Burton’s President and COO. Working closelywith Jake, Laurent led the company to continued success by capitalizing onnew and existing opportunities. Since Laurent became President in 2002,Burton has grown exponentially in key business categories, made its firstacquisition in the purchase of Four Star Distribution’s snow brands,opened a Southern California office, launched the Analog streetwear brandand opened its first retail stores in New York City and Tokyo. “I have had the great fortune to work side by side with Jake for over tenyears,” said Burton President and CEO, Laurent Potdevin. “Managing aprivately held company with such a unique culture and exceptionalopportunities is an amazing challenge. This role will allow me to focus ona rapid growth plan not only for Burton but for our family of brands.” As for Jake, he’s not going anywhere. He’ll still be at Burton doing histhing – riding, testing product and working with everyone at the companyon taking Burton to the next level. Laurent will continue to report toJake, whose official title will now be Chairman and Founder, or just’Jake’ as he prefers.last_img read more

Read More

Research uncovers new target for therapeutic intervention in breast cancer

first_imgJul 18 2018Research led by Suresh Alahari, PhD, Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has shown for the first time that a tiny piece of RNA deregulates energy metabolism, an emerging hallmark of cancer. The finding identifies a new target for therapeutic intervention in breast cancer.MicroRNAs are a class of small, single-stranded RNA molecules that play an important regulatory role in cell biology. They bind to target genes and decrease their function. MicroRNAs may act as oncogenes (a gene that contributes to cancer development) or tumor suppressors.Related StoriesResearch sheds light on sun-induced DNA damage and repairNew research links “broken heart syndrome” to cancerLiving with advanced breast cancerThe LSU Health New Orleans research team has shown that miR-27b, a novel microRNA, acts as a breast cancer oncogene. It is found in abundance in breast tumors. In this study working with a line of human breast cancer cells, they demonstrated that it suppresses the production of a protein called PDHX. PDHX is involved in cell metabolism, which among other things affects cell proliferation. Its absence allows the rapid creation of new cells, promoting tumor growth and cancer progression. The team found a significant decrease in PDHX levels in breast cancer cells.”Based on this data, we believe suppression of miR-27b is a novel approach for breast cancer therapies,” notes Dr. Alahari. “Suppression of miR-27b enhances PDHX expression, which helps in suppressing tumor progression through fixing several metabolic cascades.”According to the National Cancer Institute, there will be more cases of breast cancer diagnosed in the US in 2018 than other cancers. NCI estimates there will be 266, 120 new cases of breast cancer diagnosed and 40,920 deaths.”Using microRNA mimics or anti-miRNAs can counteract and therapeutically reverse oncogene metabolism would signify a truly unique unprecedented approach to cancer treatment,” Alahari adds. “The potential clinical uses of miRNA include utilization in diagnostic testing and disease prevention as well as prognostic markers making miRNAs unique and attractive options in the effort to reduce cancer morbidity and mortality.” Source:http://www.lsuhsc.edu/newsroom/Research%20Identifies%20New%20Breast%20Cancer%20Therapeutic%20Target.htmllast_img read more

Read More